Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes
| Indexado |
|
||||
| DOI | 10.1111/PEDI.12718 | ||||
| Año | 2018 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Danne, Thomas | Hombre |
Diabetes Zentrum Kinder & Judendl - Alemania
Diabetes-Zentrum für Kinder und Jugendliche - Alemania |
| 2 | Phillip, Moshe | Hombre |
Schneider Childrens Med Ctr Israel - Israel
Schneider Childrens Medical Center Israel - Israel |
| 3 | Buckingham, Bruce A. | Hombre |
Universidad de Stanford - Estados Unidos
Stanford University - Estados Unidos |
| 4 | Jarosz-Chobot, Przemyslawa | - |
SMK Med Univ Silesia - Polonia
Slaski Uniwersytet Medyczny w Katowicach - Polonia |
| 5 | Saboo, Banshi | - |
DiaCare Adv Diabet Care Ctr - India
DiaCare - India |
| 6 | Urakami, Tatsuhiko | Hombre |
Nihon Univ - Japón
Nihon University School of Medicine - Japón |
| 7 | Battelino, Tadej | Hombre |
Univ Ljubljana - Eslovenia
University Children's Hospital, Ljubljana - Eslovenia |
| 8 | Hanas, Ragnar | Hombre |
Gothenburg Univ - Suecia
Göteborg University, Sahlgrenska Academy - Suecia Sahlgrenska Akademin - Suecia |
| 9 | CODNER-DUJOVNE, ETHEL | Mujer |
Universidad de Chile - Chile
|
| Fuente |
|---|
| Bristol-Myers Squibb |
| Medtronic |
| Sanofi |
| Bayer |
| AstraZeneca |
| Boehringer Ingelheim |
| Merck |
| Eli Lilly and Company |
| Novo Nordisk |
| Abbott |
| Eli Lilly |
| Merck KGaA |
| BMS |
| Roche |
| Sandoz |
| Bayer/Ascentia |
| Lexicon |
| Dexcom |
| Kamada |
| Tandem |
| Insulet |
| BMS/AstraZeneca |
| Diamyd |
| Bigfoot Biomedical |
| GluSense |
| Sanofi-Aventis Deutschland |
| Agradecimiento |
|---|
| T.D. has received speaker honoraria and research support and has consulted for Abbott, Bayer, BMS, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and Roche. He is a shareholder of DreaMed Ltd. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic and Bayer Health Care. TB's Institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd. T.B. received honoraria for participating on the speaker's bureaux of Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche. T.B. owns stocks of DreamMed. B.A.B. has received research support from Medtronic, Dexcom, Insulet, Roche, Tandem, and Bigfoot Biomedical, is on advisory boards for Sanofi, NovoNordisk and Becton Dickinson and Company, and was a consultant for Dexcom. R.H. has received speaker honoraria from Novo Nordisk, Eli Lilly, Sanofi, Roche, Medtronic, DexCom, Menarini and Abbott, taken part in advisory boards for Novo Nordisk, Eli Lilly, Sanofi, Roche, Medtronic, DexCom, Menarini and Abbott and received research support from Sanofi. P.J.-C. has received speaker honoraria and research support and has consulted for Abbott, Bayer/Ascentia, BMS/AstraZeneca, Boehringer Ingelheim, DexCom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and Roche. M.P.'s institute has received grants or research support from Medtronic, Novo Nordisk, Roche, Eli Lilly, Merck, Sanofi, Bristol-Myers Squibb, Kamada, AstraZeneca, and Lexicon. M.P. has received honoraria or consultation fees from Sanofi, Medtronic, Novo Nordisk, and Eli Lilly; has participated in advisory boards for Sanofi, Medtronic, AstraZeneca, and Eli Lilly; and is a stock shareholder in DreaMed Diabetes. The remaining authors have no relevant disclosure. |
| T.D. has received speaker honoraria and research support and has consulted for Abbott, Bayer, BMS, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and Roche. He is a shareholder of DreaMed Ltd. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic and Bayer Health Care. TB's Institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd. T.B. received honoraria for participating on the speaker's bureaux of Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche. T.B. owns stocks of DreamMed. B.A.B. has received research support from Med-tronic, Dexcom, Insulet, Roche, Tandem, and Bigfoot Biomedical, is on advisory boards for Sanofi, NovoNordisk and Becton Dickinson and Company, and was a consultant for Dexcom. R.H. has received speaker honoraria from Novo Nordisk, Eli Lilly, Sanofi, Roche, Medtro-nic, DexCom, Menarini and Abbott, taken part in advisory boards for Novo Nordisk, Eli Lilly, Sanofi, Roche, Medtronic, DexCom, Menarini and Abbott and received research support from Sanofi. P.J.-C. has received speaker honoraria and research support and has consulted for Abbott, Bayer/Ascentia, BMS/AstraZeneca, Boehringer Ingelheim, DexCom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and Roche. M.P.'s institute has received grants or research support from Medtronic, Novo Nordisk, Roche, Eli Lilly, Merck, Sanofi, Bristol-Myers Squibb, Kamada, AstraZeneca, and Lexicon. M.P. has received honoraria or consultation fees from Sanofi, Medtronic, Novo Nordisk, and Eli Lilly; has participated in advisory boards for Sanofi, Medtronic, AstraZe-neca, and Eli Lilly; and is a stock shareholder in DreaMed Diabetes. The remaining authors have no relevant disclosure. |
